226 related articles for article (PubMed ID: 22122769)
21. [5-Aminosalicylic acid in ulcerative colitis and Crohn's disease (author's transl)].
Maier K; Fischer C; Klotz U; Heinkel K
Dtsch Med Wochenschr; 1982 Jul; 107(29-30):1131-4. PubMed ID: 6123426
[TBL] [Abstract][Full Text] [Related]
22. Maintenance therapy in ulcerative colitis and Crohn's disease.
Sachar DB
J Clin Gastroenterol; 1995 Mar; 20(2):117-22. PubMed ID: 7769190
[TBL] [Abstract][Full Text] [Related]
23. Self-reported frequency and severity of disease flares, disease perception, and flare treatments in patients with ulcerative colitis: results of a national internet-based survey.
Bolge SC; Waters H; Piech CT
Clin Ther; 2010 Feb; 32(2):238-45. PubMed ID: 20206781
[TBL] [Abstract][Full Text] [Related]
24. Review article: The pharmacokinetics and pharmacodynamics of drugs used in inflammatory bowel disease treatment.
Quetglas EG; Armuzzi A; Wigge S; Fiorino G; Barnscheid L; Froelich M; Danese S
Eur J Clin Pharmacol; 2015 Jul; 71(7):773-99. PubMed ID: 26008212
[TBL] [Abstract][Full Text] [Related]
25. [Therapy of chronic inflammatory bowel diseases].
Beglinger C
Ther Umsch; 1997 Nov; 54(11):649-53. PubMed ID: 9454368
[TBL] [Abstract][Full Text] [Related]
26. Chemistry, pharmacology, pharmacokinetics, and clinical applications of mesalamine for the treatment of inflammatory bowel disease.
Small RE; Schraa CC
Pharmacotherapy; 1994; 14(4):385-98. PubMed ID: 7937276
[TBL] [Abstract][Full Text] [Related]
27. Asian perspectives in the management of inflammatory bowel disease: findings from a recent survey.
Sung JJ; Kamm MA; Marteau P
J Gastroenterol Hepatol; 2010 Jan; 25(1):183-93. PubMed ID: 19929931
[TBL] [Abstract][Full Text] [Related]
28. Emerging drugs to treat Crohn's disease.
Strauch U; Schölmerich J
Expert Opin Emerg Drugs; 2010 Jun; 15(2):309-22. PubMed ID: 20402560
[TBL] [Abstract][Full Text] [Related]
29. Inflammatory bowel disease.
Hanauer SB
N Engl J Med; 1996 Mar; 334(13):841-8. PubMed ID: 8596552
[No Abstract] [Full Text] [Related]
30. [Crohn disease and ulcerative colitis--newer therapeutic approaches].
Ewe K
Z Gastroenterol; 1993 Feb; 31(2):151-5. PubMed ID: 8096666
[TBL] [Abstract][Full Text] [Related]
31. [Risk of cancer in chronic inflammatory bowel diseases].
Fischbach W
Leber Magen Darm; 1992 May; 22(3):96-101. PubMed ID: 1625513
[TBL] [Abstract][Full Text] [Related]
32. Safety and effectiveness of infliximab for inflammatory bowel diseases in clinical practice.
Tursi A; Elisei W; Brandimarte G; Giorgetti G; Penna A; Castrignano V
Eur Rev Med Pharmacol Sci; 2010 Jan; 14(1):47-55. PubMed ID: 20184089
[TBL] [Abstract][Full Text] [Related]
33. Review article: aminosalicylates in inflammatory bowel disease.
Hanauer SB
Aliment Pharmacol Ther; 2004 Oct; 20 Suppl 4():60-5. PubMed ID: 15352896
[TBL] [Abstract][Full Text] [Related]
34. Review article: new drug formulations, chemical entities and therapeutic approaches for the management of ulcerative colitis.
Ng SC; Kamm MA
Aliment Pharmacol Ther; 2008 Oct; 28(7):815-29. PubMed ID: 18627362
[TBL] [Abstract][Full Text] [Related]
35. Optimizing therapy for inflammatory bowel disease.
Robinson M
Am J Gastroenterol; 1997 Dec; 92(12 Suppl):12S-17S. PubMed ID: 9395347
[TBL] [Abstract][Full Text] [Related]
36. [Inflammatory diseases of the intestines].
Felley C; Guyot J; Hess J; Mottet C; Delarive J; Michetti P
Rev Med Suisse; 2006 Jan; 2(49):191-4, 196-8, 201-3. PubMed ID: 16493962
[TBL] [Abstract][Full Text] [Related]
37. [Aminosalicylates in chronic inflammatory intestinal diseases and rheumatoid arthritis].
Maier KP
Dtsch Med Wochenschr; 1992 Oct; 117(42):1614-5. PubMed ID: 1356747
[No Abstract] [Full Text] [Related]
38. [New developments in therapy with 5-aminosalicylic acid preparations in ulcerative colitis and Crohn disease].
Kruis W
Z Gastroenterol Verh; 1991 Mar; 26():154-6. PubMed ID: 1714132
[No Abstract] [Full Text] [Related]
39. Medical treatment of inflammatory bowel disease.
Singhal A; Kar P
J Assoc Physicians India; 1995 Sep; 43(9):627-31. PubMed ID: 8773067
[No Abstract] [Full Text] [Related]
40. Mesalamine and olsalazine: 5-aminosalicylic acid agents for the treatment of inflammatory bowel disease.
Segars LW; Gales BJ
Clin Pharm; 1992 Jun; 11(6):514-28. PubMed ID: 1600685
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
